Rosiglitazone activation of PPARγ-dependent signaling is neuroprotective in mutant huntingtin expressing cells

Experimental Cell Research

Volumn 338, Issue 2, 2015, Pages 183-193

  Chiang, Ming Chang ^a   Cheng, Yi Chuan ^b   Nicol, Christopher J ^c   Lin, Kuan Hung ^d   Yen, Chia Hui ^e   Chen, Shiang Jiuun ^f   Huang, Rong Nan ^f  

^a FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c QUEEN S UNIVERSITY   (Canada)

^d CHINESE CULTURE UNIVERSITY   (Taiwan)

^e MING CHUAN UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Huntingtin; Huntington's Disease; Neuroprotection; PGC1 ; PPAR ; Rosiglitazone

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; APOPTOSIS SIGNAL REGULATING KINASE 1; GLUCOSE REGULATED PROTEIN 78; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK TRANSCRIPTION FACTOR 1; HUNTINGTIN; MITOCHONDRIAL TRANSCRIPTION FACTOR A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEASOME; ROSIGLITAZONE; TRANSCRIPTION FACTOR NRF1; UBIQUITIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; DNA BINDING PROTEIN; HEAT SHOCK PROTEIN; HSF1 PROTEIN, MOUSE; HUNTINGTON PROTEIN, MOUSE; NERVE PROTEIN; NEUROPROTECTIVE AGENT; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; CELL FUNCTION; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION; GENE TARGETING; IN VITRO STUDY; MEDIATOR; MITOCHONDRION; NEUROBLASTOMA CELL LINE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; UBIQUITINATION; ANIMAL; BRAIN; BRAIN NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUNTINGTON CHOREA; MOUSE; NEUROBLASTOMA; TUMOR CELL LINE; UPREGULATION;

ANIMALS; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; ENDOPLASMIC RETICULUM STRESS; HEAT-SHOCK PROTEINS; HUNTINGTON DISEASE; MICE; MITOCHONDRIA; NERVE TISSUE PROTEINS; NEUROBLASTOMA; NEUROPROTECTIVE AGENTS; NUCLEAR PROTEINS; PPAR GAMMA; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; UBIQUITIN; UP-REGULATION;

EID: 84944717552     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2015.09.005     Document Type: Article

References (76)

1. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
2. Martin J.B., Gusella J.F. Huntington's disease. Pathogenesis and management. N Engl. J. Med. 1986, 315:1267-1276.
3. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 1985, 44:559-577.
4. Waelter S., Boeddrich A., Lurz R., Scherzinger E., Lueder G., Lehrach H., Wanker E.E. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol. Biol. Cell 2001, 12:1393-1407.
5. Reddy P.H., Williams M., Tagle D.A. Recent advances in understanding the pathogenesis of Huntington's disease. Trends Neurosci. 1999, 22:248-255.
6. Arrasate M., Finkbeiner S. Protein aggregates in Huntington's disease. Exp. Neurol. 2012, 238:1-11.
7. Jana N.R., Tanaka M., Wang G., Nukina N. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. Hum. Mol. Genet. 2000, 9:2009-2018.
8. Suhr S.T., Senut M.C., Whitelegge J.P., Faull K.F., Cuizon D.B., Gage F.H. Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression. J. Cell Biol. 2001, 153:283-294.
9. Borrell-Pages M., Canals J.M., Cordelieres F.P., Parker J.A., Pineda J.R., Grange G., Bryson E.A., Guillermier M., Hirsch E., Hantraye P., Cheetham M.E., Neri C., Alberch J., Brouillet E., Saudou F., Humbert S. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J. Clin. Investig. 2006, 116:1410-1424.
10. Chiang M.C., Chen H.M., Lai H.L., Chen H.W., Chou S.Y., Chen C.M., Tsai F.J., Chern Y. The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system. Hum. Mol. Genet. 2009, 18:2929-2942.
11. Hipp M.S., Patel C.N., Bersuker K., Riley B.E., Kaiser S.E., Shaler T.A., Brandeis M., Kopito R.R. Indirect inhibition of 26S proteasome activity in a cellular model of Huntington's disease. J. Cell Biol. 2012, 196:573-587.
12. Chaturvedi R.K., Beal M.F. Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases. Mol. Cell. Neurosci. 2013, 55:101-114.
13. Kouroku Y., Fujita E., Jimbo A., Kikuchi T., Yamagata T., Momoi M.Y., Kominami E., Kuida K., Sakamaki K., Yonehara S., Momoi T. Polyglutamine aggregates stimulate ER stress signals and caspase-12 activation. Hum. Mol. Genet. 2002, 11:1505-1515.
14. Nishitoh H., Matsuzawa A., Tobiume K., Saegusa K., Takeda K., Inoue K., Hori S., Kakizuka A., Ichijo H. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev. 2002, 16:1345-1355.
15. Spiegelman B.M., Flier J.S. Obesity and the regulation of energy balance. Cell 2001, 104:531-543.
16. Lazar M.A. PPAR gamma, 10 years later. Biochimie 2005, 87:9-13.
17. Lehrke M., Lazar M.A. The many faces of PPARgamma. Cell 2005, 123:993-999.
18. Bordet R., Ouk T., Petrault O., Gele P., Gautier S., Laprais M., Deplanque D., Duriez P., Staels B., Fruchart J.C., Bastide M. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem. Soc. Trans. 2006, 34:1341-1346.
19. Sundararajan S., Jiang Q., Heneka M., Landreth G. PPARgamma as a therapeutic target in central nervous system diseases. Neurochem. Int. 2006, 49:136-144.
20. Landreth G. PPARgamma agonists as new therapeutic agents for the treatment of Alzheimer's disease. Exp. Neurol. 2006, 199:245-248.
21. Martin H.L., Mounsey R.B., Mustafa S., Sathe K., Teismann P. Pharmacological manipulation of peroxisome proliferator-activated receptor gamma (PPARgamma) reveals a role for anti-oxidant protection in a model of Parkinson's disease. Exp. Neurol. 2012, 235:528-538.
22. Quintanilla R.A., Jin Y.N., Fuenzalida K., Bronfman M., Johnson G.V. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease. J. Biol. Chem. 2008, 283:25628-25637.
23. Chiang M.C., Chen C.M., Lee M.R., Chen H.W., Chen H.M., Wu Y.S., Hung C.H., Kang J.J., Chang C.P., Chang C., Wu Y.R., Tsai Y.S., Chern Y. Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma. Hum. Mol. Genet. 2010, 19:4043-4058.
24. Chiang M.C., Chern Y., Juo C.G. The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease. Biochim. Biophys. Acta 2011, 1812:1111-1120.
25. Chiang M.C., Chern Y., Huang R.N. PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease. Neurobiol. Dis. 2012, 45:322-328.
26. Chiang M.C., Lee Y.C., Huang C.L., Chern Y. cAMP-response element-binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues. J. Biol. Chem. 2005, 280:14331-14340.
27. Chiang M.C., Lin H., Cheng Y.C., Yen C.H., Huang R.N., Lin K.H. Beta-adrenoceptor pathway enhances mitochondrial function in human neural stem cells via rotary cell culture system. J. Neurosci. Methods 2012, 207:130-136.
28. Chiang M.C., Cheng Y.C., Chen H.M., Liang Y.J., Yen C.H. Rosiglitazone promotes neurite outgrowth and mitochondrial function in N2A cells via PPARgamma pathway. Mitochondrion 2014, 14:7-17.
29. Chiang M.C., Chen H.M., Lee Y.H., Chang H.H., Wu Y.C., Soong B.W., Chen C.M., Wu Y.R., Liu C.S., Niu D.M., Wu J.Y., Chen Y.T., Chern Y. Dysregulation of C/EBPalpha by mutant Huntingtin causes the urea cycle deficiency in Huntington's disease. Hum. Mol. Genet. 2007, 16:483-498.
30. Chiang M.C., Juo C.G., Chang H.H., Chen H.M., Yi E.C., Chern Y. Systematic uncovering of multiple pathways underlying the pathology of Huntington disease by an acid-cleavable isotope-coded affinity tag approach. Mol. Cell. Proteom. 2007, 6:781-797.
31. Chiang M.C., Cheng Y.C., Lin K.H., Yen C.H. PPARgamma regulates the mitochondrial dysfunction in human neural stem cells with tumor necrosis factor alpha. Neuroscience 2013, 229:118-129.
32. Chung M.M., Chen Y.L., Pei D., Cheng Y.C., Sun B., Nicol C.J., Yen C.H., Chen H.M., Liang Y.J., Chiang M.C. The neuroprotective role of metformin in advanced glycation end product treated human neural stem cells is AMPK-dependent. Biochim. Biophys. Acta 2015, 1852:720-731.
33. Cui L., Jeong H., Borovecki F., Parkhurst C.N., Tanese N., Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006, 127:59-69.
34. Puigserver P., Spiegelman B.M. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr. Rev. 2003, 24:78-90.
35. Lajoie P., Snapp E.L. Changes in BiP availability reveal hypersensitivity to acute endoplasmic reticulum stress in cells expressing mutant huntingtin. J. Cell Sci. 2011, 124:3332-3343.
36. Bortolini M., Wright M.B., Bopst M., Balas B. Examining the safety of PPAR agonists-current trends and future prospects. Expert Opin. Drug Saf. 2013, 12:65-79.
37. Combs C.K., Johnson D.E., Karlo J.C., Cannady S.B., Landreth G.E. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J. Neurosci.: Off. J. Soc. Neurosci. 2000, 20:558-567.
38. Kiaei M. Peroxisome proliferator-activated receptor-gamma in amyotrophic lateral sclerosis and Huntington's disease. PPAR Res. 2008, 2008:418765.
39. Lleo A., Galea E., Sastre M. Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases. Cell. Mol. Life Sci.: CMLS 2007, 64:1403-1418.
40. Hunt M.J., Morton A.J. Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents. Exp. Brain Res.: Experimentelle Hirnforschung 2005, 166:220-229.
41. Kalonia H., Kumar P., Kumar A. Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: possible role of peroxisome proliferator activated receptor-Upsilon (PPARUpsilon) in Huntington's disease. Pharmacol. Biochem. Behav. 2010, 96:115-124.
42. Napolitano M., Costa L., Palermo R., Giovenco A., Vacca A., Gulino A. Protective effect of pioglitazone, a PPARgamma ligand, in a 3 nitropropionic acid model of Huntington's disease. Brain Res. Bull. 2011, 85:231-237.
43. Jin Y.N., Hwang W.Y., Jo C., Johnson G.V. Metabolic state determines sensitivity to cellular stress in Huntington disease: normalization by activation of PPARgamma. PLoS One 2012, 7:e30406.
44. Jin Y.N., Johnson G.V. The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease. J. Bioenerg. Biomembr. 2010, 42:199-205.
45. Tsunemi T., La Spada A.R. PGC-1alpha at the intersection of bioenergetics regulation and neuron function: from Huntington's disease to Parkinson's disease and beyond. Prog. Neurobiol. 2012, 97:142-151.
46. Sherman M.Y., Goldberg A.L. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 2001, 29:15-32.
47. Demartino G.N., Gillette T.G. Proteasomes: machines for all reasons. Cell 2007, 129:659-662.
48. Tanaka K., Matsuda N. Proteostasis and neurodegeneration: the roles of proteasomal degradation and autophagy. Biochim. Biophys. Acta 2014, 1843:197-204.
49. Salomons F.A., Acs K., Dantuma N.P. Illuminating the ubiquitin/proteasome system. Exp. Cell Res. 2010, 316:1289-1295.
50. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001, 292:1552-1555.
51. Hegde A.N., Upadhya S.C. The ubiquitin-proteasome pathway in health and disease of the nervous system. Trends Neurosci. 2007, 30:587-595.
52. Schmidt M., Finley D. Regulation of proteasome activity in health and disease. Biochim. Biophys. Acta 2014, 1843:13-25.
53. Bennett E.J., Shaler T.A., Woodman B., Ryu K.-Y., Zaitseva T.S., Becker C.H., Bates G.P., Schulman H., Kopito R.R. Global changes to the ubiquitin system in Huntington's disease. Nature 2007, 448:704-708.
54. Wang J., Wang C.-E., Orr A., Tydlacka S., Li S.-H., Li X.-J. Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice. J. Cell Biol. 2008, 180:1177-1189.
55. Ortega Z., Diaz-Hernandez M., Lucas J.J. Is the ubiquitin-proteasome system impaired in Huntington's disease?. Cell. Mol. Life Sci.: CMLS 2007, 64:2245-2257.
56. Yang H., Zhong X., Ballar P., Luo S., Shen Y., Rubinsztein D.C., Monteiro M.J., Fang S. Ubiquitin ligase Hrd1 enhances the degradation and suppresses the toxicity of polyglutamine-expanded huntingtin. Exp. Cell Res. 2007, 313:538-550.
57. Keen H.L., Ryan M.J., Beyer A., Mathur S., Scheetz T.E., Gackle B.D., Faraci F.M., Casavant T.L., Sigmund C.D. Gene expression profiling of potential PPAR{gamma} target genes in mouse aorta. Physiol. Genom. 2004, 18:33-42.
58. Mayer M.P., Bukau B. Hsp70 chaperones: cellular functions and molecular mechanism. Cell. Mol. Life Sci.: CMLS 2005, 62:670-684.
59. Arndt V., Rogon C., Hohfeld J. To be, or not to be-molecular chaperones in protein degradation. Cell. Mol. Life Sci.: CMLS 2007, 64:2525-2541.
60. Hay D.G., Sathasivam K., Tobaben S., Stahl B., Marber M., Mestril R., Mahal A., Smith D.L., Woodman B., Bates G.P. Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum. Mol. Genet. 2004, 13:1389-1405.
61. Rujano M.A., Kampinga H.H., Salomons F.A. Modulation of polyglutamine inclusion formation by the Hsp70 chaperone machine. Exp. Cell Res. 2007, 313:3568-3578.
62. Wyttenbach A., Carmichael J., Swartz J., Furlong R.A., Narain Y., Rankin J., Rubinsztein D.C. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Sci. USA 2000, 97:2898-2903.
63. Perrin V., Regulier E., Abbas-Terki T., Hassig R., Brouillet E., Aebischer P., Luthi-Carter R., Deglon N. Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease. Mol. Ther.: J. Am. Soc. Gene Ther. 2007, 15:903-911.
64. Wacker J.L., Zareie M.H., Fong H., Sarikaya M., Muchowski P.J. Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer. Nat. Struct. Mol. Biol. 2004, 11:1215-1222.
65. Saleh A.A., Gune U.S., Chaudhary R.K., Turakhiya A.P., Roy I. Roles of Hsp104 and trehalose in solubilisation of mutant huntingtin in heat shocked Saccharomyces cerevisiae cells. Biochim. Biophys. Acta 2014, 1843:746-757.
66. Fujimoto M., Takaki E., Hayashi T., Kitaura Y., Tanaka Y., Inouye S., Nakai A. Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models. J. Biol. Chem. 2005, 280:34908-34916.
67. Park S.-W., Yi J.-H., Miranpuri G., Satriotomo I., Bowen K., Resnick D.K., Vemuganti R. Thiazolidinedione class of peroxisome proliferator-activated receptor {gamma} agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J. Pharmacol. Exp. Ther. 2007, 320:1002-1012.
68. Lindholm D., Wootz H., Korhonen L. ER stress and neurodegenerative diseases. Cell Death Differ. 2006, 13:385-392.
69. Carnemolla A., Fossale E., Agostoni E., Michelazzi S., Calligaris R., De Maso L., Del Sal G., MacDonald M.E., Persichetti F. Rrs1 is involved in endoplasmic reticulum stress response in Huntington disease. J. Biol. Chem. 2009, 284:18167-18173.
70. Reijonen S., Putkonen N., Norremolle A., Lindholm D., Korhonen L. Inhibition of endoplasmic reticulum stress counteracts neuronal cell death and protein aggregation caused by N-terminal mutant huntingtin proteins. Exp. Cell Res. 2008, 314:950-960.
71. Rao R.V., Castro-Obregon S., Frankowski H., Schuler M., Stoka V., del Rio G., Bredesen D.E., Ellerby H.M. Coupling endoplasmic reticulum stress to the cell death program. J. Biol. Chem. 2002, 277:21836-21842.
72. Choo Y.S., Johnson G.V., MacDonald M., Detloff P.J., Lesort M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet. 2004, 13:1407-1420.
73. Li S.H., Lam S., Cheng A.L., Li X.J. Intranuclear huntingtin increases the expression of caspase-1 and induces apoptosis. Hum. Mol. Genet. 2000, 9:2859-2867.
74. Varma H., Cheng R., Voisine C., Hart A.C., Stockwell B.R. Inhibitors of metabolism rescue cell death in Huntington's disease models. Proc. Natl. Acad. Sci. USA 2007, 104:14525-14530.
75. Yu Z.X., Li S.H., Evans J., Pillarisetti A., Li H., Li X.J. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J. Neurosci.: Off. J. Soc. Neurosci. 2003, 23:2193-2202.
76. Fuenzalida K., Quintanilla R., Ramos P., Piderit D., Fuentealba R.A., Martinez G., Inestrosa N.C., Bronfman M. Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J. Biol. Chem. 2007, 282:37006-37015.